University of Wollongong

Research Online
Faculty of Social Sciences - Papers

Faculty of Social Sciences

2015

The use of paracetamol (acetaminophen) among a
community sample of people with chronic
non‐cancer pain prescribed opioids
Bianca Hoban
University of New South Wales

Briony K. Larance
University of Wollongong, blarance@uow.edu.au

Natasa Gisev
University of New South Wales

Suzanne Nielsen
University of New South Wales

Milton Cohen
University of New South Wales
See next page for additional authors

Publication Details
Hoban, B., Larance, B., Gisev, N., Nielsen, S., Cohen, M., Bruno, R., Shand, F., Lintzeris, N., Hall, W., Farrell, M. & Degenhardt, L.
(2015). The use of paracetamol (acetaminophen) among a community sample of people with chronic non‐cancer pain prescribed
opioids. International Journal of Clinical Practice, 69 (11), 1366-1376.

Research Online is the open access institutional repository for the University of Wollongong. For further information contact the UOW Library:
research-pubs@uow.edu.au

The use of paracetamol (acetaminophen) among a community sample of
people with chronic non‐cancer pain prescribed opioids
Abstract

Background
The regular use of simple analgesics in addition to opioids such as paracetamol (or acetaminophen) is
recommended for persistent pain to enhance analgesia. Few studies have examined the frequency and doses of
paracetamol among people with chronic non‐cancer pain including use above the recommended maximum
daily dose.

Aims
To assess (i) the prevalence of paracetamol use among people with chronic non‐cancer pain prescribed
opioids, (ii) assess the prevalence of paracetamol use above the recommended maximum daily dose and (iii)
assess correlates of people who used paracetamol above the recommended maximum daily dose including:
age, gender, income, education, pain severity and interference, use of paracetamol/opioid combination
analgesics, total opioid dose, depression, anxiety, pain self‐efficacy or comorbid substance use, among people
prescribed opioids for chronic non‐cancer pain.

Methods
This study draws on baseline data collected for the Pain and Opioids IN Treatment (POINT) study and
utilises data from 962 interviews and medication diaries. The POINT study is national prospective cohort of
people with chronic non‐cancer pain prescribed opioids. Participants were recruited from randomly selected
pharmacies across Australia.

Results
Sixty‐three per cent of the participants had used paracetamol in the past week (95% CI = 59.7–65.8). Among
the paracetamol users 22% (95% CI = 19.3–24.6) had used paracetamol/opioid combination analgesics and
4.8% (95% CI = 3.6–6.3) had used paracetamol above the recommended maximum daily dose (i.e. > 4000
mg/day). Following binomial logistic regression (χ2 = 25.98, df = 10, p = 0.004), people who had taken above
the recommended maximum daily dose were less likely to have low income (AOR = 0.52, 95% CI =
0.27–0.99), more likely to use paracetamol/opioid combination analgesics (AOR = 2.01, 95% CI =
1.02–3.98) and more likely to take a higher opioid dose (AOR = 1.00, 95% CI = 1.00–1.01).

Conclusion
The majority of people with chronic non‐cancer pain prescribed opioids report using paracetamol
appropriately. High income, use of paracetamol/opioid combination analgesics and higher opioid dose were
independently associated with paracetamol use above the recommended maximum daily dose.
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SUMMARY

Background: The regular use of simple analgesics in addition to opioids such as paracetamol (or
acetaminophen) is recommended for persistent pain to enhance analgesia. Few studies have
examined the frequency and doses of paracetamol among people with chronic non-cancer pain
including use above the recommended maximum daily dose. Aims: To assess (i) the prevalence of
paracetamol use among people with chronic non-cancer pain prescribed opioids, (ii) assess the
prevalence of paracetamol use above the recommended maximum daily dose and (iii) assess
correlates of people who used paracetamol above the recommended maximum daily dose including:
age, gender, income, education, pain severity and interference, use of paracetamol/opioid
combination analgesics, total opioid dose, depression, anxiety, pain self-efficacy or comorbid
substance use, among people prescribed opioids for chronic non-cancer pain. Methods: This study
draws on baseline data collected for the Pain and Opioids IN Treatment (POINT) study and utilises
data from 962 interviews and medication diaries. The POINT study is national prospective cohort of
people with chronic non-cancer pain prescribed opioids. Participants were recruited from randomly
selected pharmacies across Australia. Results: Sixty-three per cent of the participants had used
paracetamol in the past week (95% CI = 59.7–65.8). Among the paracetamol users 22% (95% CI =
19.3–24.6) had used paracetamol/opioid combination analgesics and 4.8% (95% CI = 3.6–6.3) had
used paracetamol above the recommended maximum daily dose (i.e. > 4000 mg/day). Following
binomial logistic regression (v2 = 25.98, df = 10, p = 0.004), people who had taken above the
recommended maximum daily dose were less likely to have low income (AOR = 0.52, 95% CI = 0.27–
0.99), more likely to use paracetamol/opioid combination analgesics (AOR = 2.01, 95% CI = 1.02–
3.98) and more likely to take a higher opioid dose (AOR = 1.00, 95% CI = 1.00–1.01). Conclusion: The
majority of people with chronic non-cancer pain prescribed opioids report using paracetamol
appropriately. High income, use of paracetamol/opioid combination analgesics and higher opioid
dose were independently associated with paracetamol use above the recommended maximum daily
dose.

Introduction
Chronic pain is a highly prevalent condition that imposes a considerable burden on individuals and
the wider community. In Europe and the USA, the prevalence of chronic pain is approximately 19%
(1) and 31% (2) respectively. In Australia, chronic pain affects approximately 17% of women and 20%
of men (3). There have been dramatic increases in the use of prescription opioids, for example from
1
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1992 to 2007, opioid prescriptions in Australia increased by 300% (4). Despite the common use of
opioids for chronic non-cancer pain (CNCP), qualitative and quantitative reviews of opioid use in
chronic pain report that opioids may reduce pain by 30%, or 2–3 points on a 10 point analogue visual
scale (5–7), suggesting that opioid medications alone may not provide adequate pain relief.
Paracetamol is relatively inexpensive, readily available and has minimal risk of adverse events when
used at recommended doses (8,9). Use of paracetamol in conjunction with opioids can enhance
analgesia (9,10) and the World Health Organization’s (WHO) three-step pain ladder (though
originally developed for cancer pain, the recommendations are considered appropriate for other
types of pain) (11) recommends that at Step 2 and 3, round-the-clock dosing of both opioid
medication and adjuvant medications that enhance analgesia (including paracetamol) be used (12).
However, use of paracetamol above the recommended maximum daily dose (greater than 4000
mg/day) can cause adverse effects (13–15). Although paracetamol is commonly used in practice, to
date, there is a lack of literature describing the frequency of use, the range of dosages and frequency
of inappropriate use in people with CNCP.
Recently, the United States Food and Drug Administration (FDA) have limited the amount of
paracetamol per tablet in paracetamol/opioid combination analgesics to 325 mg instead of 500 mg.
This change has been made because studies on paracetamol overdoses in the USA have reported
that almost half of paracetamol overdoses are unintentional and a large proportion of overdoses
occur from combination products (16, 17). Studies have also reported that 19% of people in the USA
prescribed paracetamol/ opioid combination analgesics were at risk of liver toxicity because of
prescriptions exceeding the maximum recommended daily dose of paracetamol (13) and that
prescriptions exceeding 4000 mg/day accounted for 6–8% of all paracetamol/opioid combination
prescriptions (13,18). Literature on the associations of paracetamol and other over the counter
medication use, report that those who exceed the maximum daily dose are more likely to have
current pain, to be taking opioids or be prescribed more types of analgesics, to have depression and
anxiety and to currently smoke cigarettes (19–21).
To date, there has been minimal literature on paracetamol use and the subset of inappropriate
paracetamol use in people with CNCP prescribed opioids. Specifically, this study aims to examine: (i)
the prevalence of paracetamol use in people with CNCP prescribed opioids, as well as the range of
dosages and the types of combination products used (ii) the prevalence of paracetamol use above
the recommended maximum daily dose and (iii) whether demographic characteristics, pain severity
and interference with daily activities, use of paracetamol/opioid combination analgesics, total opioid
dose, mental health and comorbid substance use, are associated with paracetamol use above the
recommended maximum daily dose.

Methods
Study Design
This paper uses data from the Pain and Opioids IN Treatment (POINT) study. The POINT study is a
national prospective cohort that aims to follow 1500 people with CNCP prescribed opioids over a 24month period. For a detailed description of the POINT study protocol, see Campbell et al. (22). In
brief, participants were recruited from randomly selected Australian pharmacies. Eligible
2
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participants had chronic pain (defined as persistent pain for 3 months or more), were currently
prescribed opioids for at least 6 weeks, were not currently suffering from cancer, and were not
currently undergoing opioid substitution treatment for the management of opioid dependence
developed through heroin use.
The major aims of the POINT study are to examine the natural history of prescribed opioid use;
examine the predictors of adverse events; and identify factors that predict poor self-reported pain
relief and other outcomes. The study was approved by the Human Research Ethics Committee of the
University of New South Wales (HREC reference: # HC12149).

Recruitment
Research staff randomly contacted 5532 pharmacies (93% of pharmacies across Australia) for
expressions of interest to recruit for the study, 1868 (34%) agreed to help with recruitment and of
those pharmacies that agreed to recruit, 480 (26%) actively recruited. Pharmacists were asked to
hand out flyers to customers who came into the pharmacy to fill a Schedule 8 opioid prescription
and interested customers then left their details for contact by the research team to be made.
Schedule 8 opioids are opioids subject to strict regulatory controls regarding their manufacture,
supply, distribution, possession and use (23). These opioids included: buprenorphine, codeine (30
mg codeine tablets or codeine linctus), fentanyl, hydromorphone, morphine and oxycodone.
From this referral method, 2318 people expressed an interest, 1262 (54%) participated in the study,
310 (13%) were ineligible, 343 (15%) refused to participate and 403 (17%) could not be contacted. Of
those who were ineligible, 132 (43%) felt they were too unwell to participate, 9 (3%) did not speak
English, 105 (34%) had not been prescribed opioids for 6 weeks, 40 (13%) were suffering from
cancer, six (2%) were receiving opioid substitution treatment for heroin dependence and 18 (6%) did
not meet study criteria for suffering from chronic pain (defined as pain lasting 3 months or longer).
Of the participants who completed the baseline interview and had adequate time to complete and
return the study pack, 962 (74%) returned the medication diary.

Medication use
Daily dose and days of use in the past week for all prescribed and non-prescribed medications were
collected via a 1 week self-complete medication diary, which participants were asked to complete in
the same week that they completed the phone and baseline self-report survey. A total daily
paracetamol dose was calculated from the medication diary for each person by adding the dose of
paracetamol present in all paracetamol-containing medications (including combination products) for
each day in the last week. Use above 4000 mg on any day was considered use above the
recommended maximum daily dose (24).
A protocol for converting the mean daily opioid doses to oral morphine equivalent dose was
constructed for the POINT study (see Appendix 1) (25). A mean daily dose was calculated for each
opioid medication by dividing the total weekly dose by the number of days of use. The mean daily
doses for each of the opioids were converted to oral morphine equivalent doses (in milligram
3
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morphine equivalent units). The oral morphine equivalent doses were then added together to create
a total daily opioid dose. Dose conversion ratios were cross-checked from the Therapeutic
Guidelines (26), Australian Medicines Handbook (27) and a consensus document developed by the
faculty of Pain Medicine of the Australian and New Zealand College of Anaesthetists (FPMANZCA).
Where there was non-concordance between the three references, precedence was given to
recommendations by the Therapeutic Guidelines and in the case of methadone, Walker et al. (28)
was used for calculating oral morphine equivalent doses.

Covariates
Participant demographics were self-report variables obtained from the baseline phone interview and
included age, gender, education, chronic pain condition and current income. Income was reported
as greater than or less than/equal to $399/week, which is approximately equivalent to the weekly
allowance of government pensions. Also used in the analysis were baseline interview variables from
the: Brief Pain Inventory (BPI) for pain severity and interference (29); Patient Health Questionnaire 9
item (PHQ9) scale for Depression (30,31); Generalized Anxiety Disorder 7 item (GAD-7) scale (32);
the Pain Self-Efficacy Questionnaire (PSEQ) (33) and the Opioid-Related Behaviours in Treatment
(ORBIT) scale (34).

Pain severity and interference
The BPI measures pain severity using an 11 point scale and participants rate the worst, least and
average pain experienced in the last week as well as current pain level. These measures are
presented individually and as a total mean pain severity score. The BPI also measures the degree of
relief provided by all medications and treatments provided in the last week as a percentage.
Participants also rate the level of interference pain causes to activities on an 11 point scale; including
general activity, mood, walking ability, work, relationships, sleep and enjoyment of life. A mean
interference score was then calculated for participants who answered 50% or more of the questions
(29,35,36).

Symptoms of anxiety and depression
PHQ-9 and GAD-7 measure the severity of the 9 DSM-V depressive symptoms and 7 symptoms of
anxiety over the last 2 weeks. The severity of depression or anxiety was calculated by the sum of
scores for each response to a symptom of depression or anxiety. PHQ-9 and GAD-7 scores greater
than 10 meet criteria for moderate to severe depression or anxiety symptoms (30,31).

Pain self-efficacy questionnaire
All participants were asked 10 questions regarding their confidence to do a variety of activities
‘despite their pain’. The activities included physical activities (completing chores, working, becoming
more active and socialising) as well as emotional experiences (accomplishing goals, coping with pain
4
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and enjoying things). These questions were scored on a 7 point scale where 0 means ‘not at all
confident’ and 6 means ‘completely confident’. A total score is calculated by the sum of these scores
(33).

Aberrant opioid-related behaviours
All participants were asked 10 questions regarding aberrant opioid-related behaviours over the
preceding 3 months. These were scored dichotomously and added to give a total score using the
Opioid-Related Behaviours in Treatment (ORBIT) scale (e.g. ‘Over the past 3 months, I have asked my
doctor for an increase in my prescribed dose’). The ORBIT scale was developed for use among
Australian people receiving opioids for pain or opioid dependence in both clinical and research
settings. The scale has demonstrated strong internal consistency (Cronbach’s alpha = 0.85) (34).

Statistical analysis
Analyses were conducted using IBM SPSS statistics version 22 (SPSS, Inc., Chicago, IL, USA). At
bivariate level, continuous variables were compared with paracetamol use below and above the
recommended maximum daily dose using the independent samples t-test and Mann–Whitney U for
all non-normally distributed variables. Categorical variables were compared using odds ratios (ORs).
All significance tests were two-sided and conducted at a 0.05 significance level. A logistic regression
analysis was used to examine predictors of paracetamol use in excess of maximum recommended
daily doses. Variables that were included in the model were demographic variables (sex and age) and
all variables in the bivariate analysis that had a p-value less than 0.25. Linearity assumption tests (37)
were also conducted for all continuous variables in the model using the BoxTidwell (1962) procedure
(38).

Results
Demographics and health characteristics
The mean age of the participants was 59 years (SD 13.3) and ranged from 21 to 94 years. Over half
were female (57%, 95% CI = 53.4–59.7), about one-third
(34%, 95% CI = 31.4–37.4) were retired, 47% (95%
CI = 43.6–50.2) were unemployed and 60% (95% CI = 57.3–63.4) had a weekly income of $399 or
less. Almost two-thirds (61%, 95% CI = 58.2–63.4) reported changing their employment in some way
because of their pain condition. Participants had been living with chronic pain for a median of 10
years (ranging between 0 and 72 years) and 73% (95% CI = 70.6–76.2) have had two or more
problematic chronic pain conditions in the last 12 months. In addition to experiencing chronic pain,
51% (95% CI = 48.1–54.4) of participants reported having an additional problematic physical
condition in the last 12 months, for example, problems relating to stroke, heart attack, sleep
apnoea, heart disease, hypertension, chronic respiratory diseases, diabetes, HIV, epilepsy, seizures
and cancer. Furthermore, 44% (95% CI = 41.1–47.3) met criteria for current moderate to severe
5
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depression and 22% (95% CI = 18.8–24.0) met criteria for current moderate to severe generalised
anxiety disorder (Table 1).

Medication use
The most commonly used opioids were oxycodone (56%, 95% CI = 52.7–58.9) and buprenorphine
(21%, 95% CI = 18.8–24.0; Table 2). In addition,
25% (95% CI = 22.5–28.0) were taking another opioid, with codeine combinations (17%, 95% CI =
14.9–19.7) the most common. The median total daily opioid dose was 68 mg (IQR = 106 mg) and
ranged from 0 mg to 800 mg. In addition to the opioids, over half of all participants (56%, 95% CI =
52.3–58.6) had taken antidepressants and a quarter had taken antiepileptic (27%, 95% CI = 24.0–
29.6) or benzodiazepine medications (26%, 95% CI = 23.6–29.2) in the last week.
In addition to prescribed medications, 64% (95% CI = 60.5–66.7) of participants also reported using
over the counter strength analgesic medications in the last week, with the most prevalent being
medications containing paracetamol (50%, 95% CI = 47.3– 53.6). When prescription only forms of
paracetamol were included [for example, paracetamol/codeine combinations containing ≥ 30 mg of
codeine per tablet (23)], 63% (95% CI = 59.7–65.8) had taken some form of paracetamol in the last
week.
The most common form of paracetamol was paracetamol as the only active ingredient (47%, 95% CI
= 43.6–49.9; Figure 1). About one-fifth of the sample (22%, 95% CI = 19.3–24.6) had taken some type
of paracetamol combination product in the past week, with prescription only paracetamol/codeine
combination products [contain ≥ 30 mg of codeine per tablet/unit (23)] the most commonly used
paracetamol combination product (17%, 95% CI = 14.4–
19.1) used.
The mean daily paracetamol dose in the past week for all paracetamol users in the sample was 2501
mg (SD 1470 mg) and 6.1% of paracetamol users (or 35 participants) had used more than 4000
mg/day on average in the past week (Figure 2). The majority of participants who used paracetamol
in the past week used an average of 3000 mg or less per day, with just under one-third of
participants taking between 3001 and 4000 mg/day on average in the past week (31%, 95% CI =
27.5–35.0).
Forty-six participants (4.8%, 95% CI = 3.6–6.3) had taken greater than 4000 mg of paracetamol on at
least 1 day in the last week and accounted for 8.0% of all paracetamol users (95% CI = 6.1–10.6).
Within this group doses ranged from 0 mg to 9540 mg on any day in the last week, however, twentyfour (52.0%, 95% CI = 38.1–65.9) of the forty-six participants had taken more than 4000 mg of
paracetamol every day in the last week. The mean daily dose of paracetamol for those who had
taken greater than 4000 mg on any day in the last week was 4616 mg (SD 1396 mg).
Participants who had taken greater than 4000 mg on any day in the last week were compared with
those who had taken paracetamol in the last week but did not exceed 4000 mg on any day (Table 3).
Variables with a p-value less than 0.25 in the bivariate analysis as well as sex were included in the
6
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multivariate binomial logistic regression model (age, income, mean pain severity, pain interference,
relief from medications, paracetamol/opioid medication use, opioid dose, depression and pain selfefficacy). Income, paracetamol/opioid combination product use and higher opioid dose were
significantly associated with paracetamol use above 4000 mg on any day in the last week. The model
was statistically significant (v2 = 25.98, df = 10, p = 0.004) and explained 11% (Nagelkerke R2) of the
variance in paracetamol use above the recommended maximum daily dose. The model correctly
classified 92.3% of cases, the sensitivity was 2.3% and the specificity was 100%, the positive
predictive value was 100% and the negative predictive value was 92.2%. Participants with current
income below $399/week had half the odds (Adjusted OR = 0.52, 95% CI = 0.27–0.99) compared to
those with higher income of taking greater than 4000 mg of paracetamol on any day in the last
week. Participants taking a paracetamol/opioid combination analgesics had twice the odds (Adjusted
OR = 2.01, 95% CI = 1.02–4.00) compared to those who did not use combination analgesics of taking
greater than 4000 mg of paracetamol on any day in the last week. Total opioid dose was also
statistically significant in the multivariate model; however, the odds was only 1.003 (rounded to
1.00, 95% CI = 1.00–1.01). A linearity assumption test confirmed that total opioid dose (as well as all
the other

Continuous variables in the model) is linearly related to paracetamol use above 4000 mg on any day
in the past week. A graph of the log odds was also plotted against the range of total opioid dose
(Figure 3). The graph illustrates that the log odds is linearly related and that the odds ratio is small
because of a unit increase over the range of the continuous variable. The odds at the highest total
opioid dose (800 mg/ day) in the sample increases to 2.4. Participants taking greater than 4000 mg
of paracetamol on any day in the last week were more likely to have a higher total opioid dose.
Figure 1 Paracetamol source according to the baseline self-report 1 week medication diary of people
with chronic noncancer pain prescribed opioids from the pain and opioids in treatment (POINT) study.
Paracetamol/codeine refers to nonprescription strength combinations (< 30 mg of codeine per
tablet). Other prescription only paracetamol products included dextropropoxyphene/paracetamol
and orphenadrine/paracetamol
Figure 2 Mean daily paracetamol doses according to a self-report 1 week medication diary as a
proportion of all paracetamol users in the pain and opioids in treatment (POINT) study
Figure 3 Graph of the logistic regression log odds of the oral morphine equivelant daily dose (mg/day)
in the past week and paracetamol use above reccomended maxinum daily doses (outcome) using the
pain and opioids in treatment (POINT) study

Discussion
This is the first Australian study to examine use of paracetamol (acetaminophen) among a
community sample of people with chronic non-cancer pain. The majority of participants had taken
paracetamol in the last week and the most common paracetamol product used contained
paracetamol as the only active ingredient, followed by prescription only paracetamol/codeine
combination products. A minority had taken greater than 4000 mg on any day in the last week.
Those exceeding the recommended maximum daily dose of paracetamol were more likely to have
7
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an income greater than $399/ week, to have taken paracetamol/opioid combination analgesics and
to be taking a higher dose of opioids.
The reported prevalence of paracetamol and non-opioid medication use above the recommended
maximum daily dose varies in the literature from 3.4% to 14% (19,21,39), presumably as a result of
different sampling frames and differing use of paracetamol/opioid combination products available in
different countries (for example, paracetamol/hydrocodone is not available in Australia but is in the
USA). Two US studies (19,39) reported the prevalence of paracetamol use above the recommended
maximum daily dose (4.5% and 3.4%), whereas, a Belgian study (21) reported the prevalence of all
medication use above recommended maximum daily doses (14%) in a cohort of people with CNCP.
One of the US studies (19) examined paracetamol users whereas the other two studies (21,39)
examined CNCP samples, however, the study on paracetamol users reported an association with
CNCP. Although there are differences in the samples used in the literature and this study, they all
identify a small group of people who use paracetamol or non-opioid medications above
recommended maximum daily doses for CNCP.
The association between use of paracetamol above the recommended maximum daily dose and use
of paracetamol/opioid combination analgesics, appears to support previous studies that reported
about onefifth of people who receive prescribed paracetamol/ opioid combination products are
exceeding 4000 mg paracetamol per day (13). However, unlike the US studies, we do not know
whether the scripts people were given exceeded 4000 mg/day or whether they took additional OTC
paracetamol or extra prescribed paracetamol products to increase the daily dose above 4000 mg
(13,18). While, the results of this study seem to support the FDA’s decision to decrease the dose in
paracetamol/opioid combination products it must be stated that a 325 mg dose of paracetamol is
sub-therapeutic and by using paracetamol and opioids separately, the doses can be titrated to an
individual’s pain response.
The association between use of paracetamol above the recommended maximum daily dose and
higher total opioid dose although statistically significant in the multivariate model, did not appear to
be clinically significant. However, the plot of the log odds demonstrated the unit increase associated
with total opioid dose. This means that a single unit increase in total opioid dose (1 mg) does not
have a clinically meaningful effect, however, a large increase does. The association between total
opioid dose and paracetamol use above the recommended maximum daily dose is consistent with
other study findings (13,15,21). This suggests that people who use paracetamol above the
recommended maximum daily dose may be more reliant on medications to relieve their pain.
Studies have reported that the majority of participants, who had used above the recommended
maximum daily dose of paracetamol, did so to achieve adequate pain relief (40,41) and reviews on
the effectiveness of opioid medications report only a modest level of pain relief (5–7). The
association with higher opioid dose and paracetamol use above the recommended maximum daily
dose suggests that there are a group of patients for which medications may not provide sufficient
pain relief, and for whom other non-medication based treatments may be particularly important.
This study is the first to find an association between use of paracetamol above the recommended
maximum daily dose and income. This finding could be explained by differences in the healthcare
system in Australia. The Australian healthcare system publicly subsidises prescriptions for some OTCstrength analgesic medications (including some paracetamol products) to people who suffer from
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chronic arthropathies (34) or if they have a healthcare card (given to low income earners who
receive a government pension) (42). The cut-off for income used in this study (i.e., less than
AUS$399/week) is approximately comparable with the income from unemployment or disability
benefits. As a result, it is likely that there are more healthcare card holders among the lower income
group, and medical practitioners and pharmacists may supervise paracetamol use more closely
among this group. Unlike other studies (15,30), we did not find an association with smoking status at
bivariate level, possibly because of a low smoking prevalence in Australia compared with that
observed in different countries (33).
This is the first Australian study of its scale to provide a context for paracetamol use in people living
in the community with CNCP, reporting on a 1 week snapshot of medication use. As such, we do not
know if the observed patterns are typical of paracetamol and opioid use over a longer time period.
As the study has no measure of liver function, we also cannot comment on outcomes (such as
hepatotoxicity) that may be important in better understanding adverse effects that may be
associated with higher than recommended doses of paracetamol. However, a previous study in the
USA on paracetamol/opioid combination prescriptions exceeding 4000 mg/day have indicated that a
small proportion (n = 3818, 0.1%) of users developed liver dysfunction in the study period. Although
this number is small, those who had a script exceeding 4000 mg/day of paracetamol accounted for
23% (n = 894) of the sub-sample with liver dysfunction (13). In addition, it is possible that some
participants were reluctant to disclose paracetamol use or daily dose; however, paracetamol use is
not stigmatised like adherence to opioid treatment and all participants were informed that the
interviews were confidential, de-identified and that their responses would not affect their medical
treatment. Self-report of medication dose is subject to the possibility of recall bias (43); however,
this is unlikely as participants were sent the diary before the interview and previous research on the
topic has reported low rates of over reporting (1%) (44). In addition, self-report data are the best
available data for this current study as patients’ prescribing records would not capture over the
counter and/ or PRN medication use. The POINT study is a longitudinal study and in the future it may
be possible to examine paracetamol use over a 24-month period and link use to adverse outcomes in
linked data sets for the cohort.
This study identified that a large proportion of people with CNCP prescribed opioids, use
paracetamol (63%). Paracetamol as the only active ingredient was the most commonly used form of
paracetamol (47%), followed by paracetamol/ codeine combination products (22%). While the
majority of paracetamol users used less than 3000 mg of paracetamol per day, this study also
identified a small group of people that were using paracetamol above the recommended maximum
daily dose (4.8% of the sample or 8.0% or paracetamol users, used >4000 mg on at least 1 day in the
past week). Those who had taken paracetamol above the recommended maximum daily dose were
less likely to have a low income, more likely to have a higher total opioid dose and more likely to use
a paracetamol/opioid combination analgesic. These findings have important clinical implications,
namely that health professionals should actively question paracetamol use in people with CNCP
prescribed opioids, particularly if they perceive their medication regime to be inadequate or use a
paracetamol/opioid combination analgesic.

Acknowledgements
9

Author postprint of Hoban, B., …, Hall, W., Farrell, M., & Degenhardt, L. (2015). The use of paracetamol
(acetaminophen) among a community sample of people with chronic non-cancer pain prescribed opioids. Int J
Clin Practice, 69, 1366-76. 10.1111/ijcp.12716. Please refer to published version for tables mentioned in the text.

We thank Gabrielle Campbell, Jessica Belcher, Sarah Freckleton, Anika Martin, Ranira Moodley,
Kimberley Smith and Rachel Urquhart-Secord, NDARC, for their contribution to data collection. We
also thank Cerissa Papanastasiou, Burnet Institute, for her contribution to some of the POINT data
collection in Melbourne. We thank the Pharmacy Guild of Australia, the NSW Pharmacy Guild and
Pain Australia, for their support of this study and assistance with dissemination. We also thank the
POINT advisory committee for their advice on the design and conduct of the study.
This study received funding from the Australian National Health and Medical Research Council
(NHMRC, #1022522). L.D., B.L., S.N., N.G. and W.H. are supported by NHMRC research fellowships
(#1041472, #1073858, #1013803, #569738, #1091878 and #1045318). The National Drug and
Alcohol Research Centre at the University of NSW was supported by funding from the Australian
Government under the Substance Misuse Prevention and Service Improvements Grant Fund. Cerissa
Papanastasiou was supported by funding provided to Paul Dietze and L.D. by the Victorian Drug Law
Enforcement Fund.
Principal Investigator: Louisa Degenhardt.
Authors’ contributions
B.H., L.D., B.L., S.N. and N.G. led writing for the first draft. All authors contributed to the critical
review of the manuscript. L.D., R.B., N.L., M.F., M.C., W.H., B.L., S.N. and F.S. contributed to the
development of the study for the purposes of the funding proposal and development of the study
design.

References
1

Breivik H, Collett B, Ventafridda V, Cohen R, Gallacher D. Survey of chronic pain in Europe:
prevalence, impact on daily life, and treatment. Eur J Pain 2006; 10(4): 287–333.

2

Johannes CB, Le TK, Zhou X, Johnston JA, Dworkin RH. The prevalence of chronic pain in
United States Adults: results of an Internet-based survey. J Pain 2010; 11(11): 1230–9.

3

Blyth FM, March LM, Brnabic AJ, Jorm LR, Williamson M, Cousins MJ. Chronic pain in
Australia: a prevalence study. Pain 2001; 89(2–3): 127–34.

4

Leong M, Murnion B, Haber PS. Examination of opioid prescribing in Australia from 19922007. Intern Med J 2009; 39(10): 676–81.

5

Noble M, Treadwell J, Tregear S et al. Long-term opioid management for chronic noncancer
pain. Cochrane Database Syst Rev 2010; 1(CD006605AU): 1–68.

6

Chou R, Franciullo GJ, Fine PG et al. 2009 Clinical Guidelines from the American Pain Society
and the American Academy of Pain Medicine on the use of chronic opioid therapy in chronic
noncancer pain: what are the key messages for clinical practice? Pol Arch Med Wewn 2009;
119 (7–8): 8.

7

Kalso E, Edwards JE, Moore RA, McQuay H. Opioids in chronic non-cancer pain: systematic
review of efficacy and safety. Pain 2004; 112(3): 372–80.
10

Author postprint of Hoban, B., …, Hall, W., Farrell, M., & Degenhardt, L. (2015). The use of paracetamol
(acetaminophen) among a community sample of people with chronic non-cancer pain prescribed opioids. Int J
Clin Practice, 69, 1366-76. 10.1111/ijcp.12716. Please refer to published version for tables mentioned in the text.

8

Lavonas EJ, Fries JF, Furst DE et al. Comparative risks of non-prescription analgesics: a
structured topic review and research priorities. Drug Saftey 2012; 11(1): 33–44.

9

Barkin RL. Acetaminophen, aspirin, or ibuprofen in combination analgesic products. Am J
Ther 2001; 8(6): 433–42.

10

Filitz J, Ihmsen H, Gu€nther W et al. Supra-additive effects of tramadol and acetaminophen
in a human pain model. Pain 2008; 136(3): 262–70.

11

Vargas-Schaffer G. Is the WHO analgesic ladder still valid?: twenty-four years of experience.
Can Fam Physician 2010; 56(6): 514–7.

12

Cancer Pain Relief: With a Guide to Opioid Availability Geneva World Health Organization
(WHO) 1996 [updated 14 March 2014].
http://whqlibdoc.who.int/publications/9241544821.pdf (accessed 25 March 2014).

13

Mort JR, Shiyanbola OO, Ndehi LN, Xu Y, Stacy JN. Opioid-paracetamol prescription patterns
and liver dysfunction. Drug Saf 2011; 34(11): 1079–88.

14

Duh MS, Vekeman F, Korves C et al. Risk of hepatotoxicity-related hospitalizations among
patients treated with opioid/acetaminophen combination prescription pain medications.
Pain Med 2010; 11 (11): 1718–25.

15

Bond GR, Ho M, Woodward RW. Trends in hepatic injury associated with unintentional
overdose of paracetamol (acetaminophen) in products with and without opioid: an analysis
using the National Poison Data System of the American Association of Poison Control
Centers, 2000-7. Drug Saf 2012; 35 (2): 149–37.

16

FDA recommends health care professionals discontinue prescribing and dispensing
prescription combination drug products with more than 325 mg of acetaminophen to
protect consumers [Internet].

U.S. Food and Drug Administration, 2014. http:// www.fda.gov/Drugs/DrugSafety/ucm381644.htm
(accessed 18 March 2014).
17

FDA Drug Safety Communication: Prescription Acetaminophen Products to be Limited to 325
mg Per Dosage Unit; Boxed Warning Will Highlight Potential for Severe Liver Failure, 2011.

18

Albertson TE, Walker VM Jr, Stebbins MR, Ashton EW, Owen KP, Sutter ME. A population
study of the frequency of high-dose acetaminophen prescribing and dispensing. Ann
Pharmacother 2010; 44(7–8): 1191–5.

19

Kaufman DW, Kelly JP, Rohay JM, Malone MK, Weinstein RB, Shiffman S. Prevalence and
correlates of exceeding the labeled maximum dose of acetaminophen among adults in a USbased internet survey. Pharmacoepidemiol Drug Saf 2012; 21 (12): 1280–8.

20

Boudreau RM, Hanlon JT, Roumani YF et al. Central nervous system medication use and
incident mobility limitation in community elders: the Health, Aging, and Body Composition
study. Pharmacoepidemiol Drug Saf 2009; 18(10): 916–22.

11

Author postprint of Hoban, B., …, Hall, W., Farrell, M., & Degenhardt, L. (2015). The use of paracetamol
(acetaminophen) among a community sample of people with chronic non-cancer pain prescribed opioids. Int J
Clin Practice, 69, 1366-76. 10.1111/ijcp.12716. Please refer to published version for tables mentioned in the text.

21

Broekmans S, Dobbels F, Milisen K, Morlion B, Vanderschueren S. Determinants of
medication underuse and medication overuse in patients with chronic non-malignant pain: a
multicenter study. Int J Nurs Stud 2010; 47(11): 1408–17.

22

Campbell G, Mattick R, Bruno R et al. Cohort protocol paper: the Pain and Opioids In
Treatment (POINT) study. BMC Pharmacol Toxicol 2014; 15 (1): 17.

23

Poisons Standard 2015: Standard for the Uniform Scheduling of Medicines and Poisons No.6
(THE SUSMP 6) [Internet]. Therapeutic Goods Administration, 2015.
http://www.comlaw.gov.au/Details/F2015L00128 (accessed 5 May 2015).

24

Paracetamol [Internet]. Therapeutic Guidelines Limited, 2013.
http://etg.tg.com.au/ip/desktop/index.htm (accessed 6 February 2014).

25

Nielsen S, Degenhardt L, Hoban B, Gisev N. Comparing opioids: A guide to estimating oral
morphine equivalents (OME) in research. National Drug and Alcohol Research Centre,
University of NSW, 2014. Contract No.: Technical Report No. 329.

26

Analgesics used in chronic nonmalignant pain [Internet]. Therapeutic Guidelines Limited,
2013. http://etg.tg.com.au/ip/desktop/index.htm (accessed 14 March 2014).

27

Australian Medicines Handbook 2013 online. [Internet]. Australian Medicines Handbook Pty
Ltd, 2013. http://www.amh.net.au/online/view.php?page=chapter3/tablecomp-infopioid.tb.html (accessed 1 March 2014).

28

Walker P, Palla S, Pei B et al. Switching from methadone to a different opioid: what is the
equianalgesic dose ratio. J Palliat Med 2008; 11(8): 6.

29

Cleeland C, Ryan K. Pain assessment: global use of the Brief Pain Inventory. Ann Acad Med
Singapore 1994; 23(2): 129.

30

Kroenke K, Spitzer RL, Williams JB. The PHQ-9: validity of a brief depression severity
measure. J Gen Intern Med 2001; 16(9): 606–13.

31

Kroenke K, Spitzer RL, Williams JBW, Lo€we B. The patient health questionnaire somatic,
anxiety, and depressive symptom scales: a systematic review. Gen Hosp Psychiatry 2010;
32(4): 345–59.

32

Spitzer RL, Kroenke K, Williams JBW, Lowe B. A brief measure for assessing generalized
anxiety disorder: the GAD-7. Arch Intern Med 2006; 166(10): 1092–7.

33

Nicholas MK. The pain self-efficacy questionnaire: taking pain into account. Eur J Pain 2007;
11(2): 153–63.

34

Larance B, Bruno R, Lintzeris N et al. Development of a brief tool for monitoring aberrant
behaviours among patients receiving long-term opioid therapy: the Opioid-Related
Behaviours In Treatment (ORBIT) scale. Pain. Submitted

35

Turk DC, Dworkin RH, Burke LB et al. Developing patient-reported outcome measures for
pain clinical trials: IMMPACT recommendations. Pain 2006; 125(3): 208–15.

12

Author postprint of Hoban, B., …, Hall, W., Farrell, M., & Degenhardt, L. (2015). The use of paracetamol
(acetaminophen) among a community sample of people with chronic non-cancer pain prescribed opioids. Int J
Clin Practice, 69, 1366-76. 10.1111/ijcp.12716. Please refer to published version for tables mentioned in the text.

36

Turk DC, Dworkin RH, Revicki D et al. Identifying important outcome domains for chronic
pain clinical trials: an IMMPACT survey of people with pain. Pain 2008; 137(2): 276–85.

37

Hosmer DW, Lemeshow S, Sturdivant RX. Applied Logistic Regression. Hoboken: Wiley, 2013.
http:// unsw.eblib.com/patron/FullRecord.aspx? p = 1138225.

38

Box G, Tidwell P. Transformation of the independent variables. Technometrics 1962; 4: 531–
550.

39

Boudreau DM, Wirtz H, Von Korff M, Catz SL, St John J, Stang PE. A survey of adult awareness
and use of medicine containing acetaminophen. Pharmacoepidemiol Drug Saf 2013; 22(3):
229–40.

40

Fosnocht D, Taylor JR, Caravati EM. Emergency department patient knowledge concerning
acetaminophen (paracetamol) in over-the-counter and prescription analgesics. Emerg Med J
2008; 25(4): 213–6.

41

Ayonrinde OT, Phelps GJ, Hurley JC, Ayonrinde OA. Paracetamol overdose and hepatotoxicity
at a regional Australian hospital: a 4-year experience. Intern Med J 2005; 35(11): 655–60.

42

Health Care Card [Internet]. Department of Human Services.
http://www.humanservices.gov.au/customer/services/centrelink/health-care-card
(accessed 26 March 2014).

43

Chan D. So why ask me? Are Self-Report Data Really That bad? Statistical and
Methodological Myths and Urban Legends: Doctrine, Verity and Fable in the Organizational
and Social Sciences. New York: Taylor and Francis, 2009.

44

Loo R, Chan Q, Brown IJ et al. A comparison of self-reported analgesic use and detection of
urinary ibuprofen and acetaminophen metabolites by means of metabonomics: the
INTERMAP Study. Am J Epidemiol 2012; 175(4): 348–58.

13

